CLEARMIND MEDICINE INC
CMNDNASDAQTrading Snapshot
- Day Range
- $0.79 – $0.80
- 52-Week Range
- $0.77 – $480.00
- Volume
- $3.30B
- Avg Volume
- $3.08B
- Shares Outstanding
- 1.5M
- Next Earnings
- Oct 31, 2026
Fundamentals Snapshot
- Annual Revenue
- $436,312
- Last Q Revenue
- $121,335
- P/E Ratio
- -0.1
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-4.74
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +35.5%
Why Investors Own CMND
- ✓High-growth profile — revenue up +7.9% YoY with expanding US Equity exposure.
- ✓Healthy economics — 63% gross margin and 17% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
CLEARMIND MEDICINE INC
CMND
StockOtter · stockotter.spaceAbout CLEARMIND MEDICINE INC
Clearmind Medicine Inc. is a pre-clinical biopharmaceutical company dedicated to pioneering the development of novel psychedelic-based treatments. Their primary goal is to address a variety of mental health and addiction challenges that currently lack adequate solutions. The company's research targets conditions such as alcohol use disorder (including problematic binge drinking), various eating disorders (like binge eating), depression, and other compulsive or "binge" behaviors. Founded in 2017, the company initially operated under the name Cyntar Ventures Inc. before officially rebranding as Clearmind Medicine Inc. in March 2021. Its operations are headquartered in Vancouver, Canada.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations
The U.S. patent applications cover proprietary combinations of NeuroThera's PEA technology with LSD, ketamine and ibogaine for potential therapeutic applications, including mental health disorders, such as depression and
Clearmind Enhances U.S. IP Presence with Publication of Three Patent Applications Covering LSD, Ketamine and Ibogaine Combinations
The covered applications address potential therapeutic uses across a range of indications, including mental health disorders, such as depression and PTSD as well as substance use disorders
Stickit Technologies Announces Corporate Update: Leadership Appointments, Capital Restructuring & Loan Acquisition, And Update Of Intellectual Property Portfolio
VANCOUVER, BC September 17, 2026 - TheNewswire — StickIt Technologies Inc. (CSE: STKT) (the "Company" or "StickIt"), a developer and patent holder of proprietary cannabinoid and plant extract delivery technologies, today
Clearmind Medicine Delivers Briefing to FDA Following Invitation to Historic Psychedelic Hearing in Washington, D.C.
Mary-Elizabeth Gifford, Chief of Global Impact at Clearmind Medicine, spoke on patient access and shared insights from Clearmind's clinical trial at Yale and Johns Hopkins
Clearmind Enrolls First Patients with Alcohol Use Disorder in CMND-100 Clinical Trial
Vancouver, Canada, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (the “Company”), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogen for
Clearmind Medicine Receives Yale IRB Approval, Enabling Patient Recruitment for Parts B and C of CMND-100 Phase I/II Trial, Following Positive Safety Results
Vancouver, Canada, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (the “Company” or “Clearmind”), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neu